GleamWall
中文EN

PRCT PROCEPT BioRobotics Corp

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1588978 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.5%
TTM net income YoY-35.8%
TTM EPS YoY-32.0%
Revenue 3-yr CAGR44.7%
Net income 3-yr CAGR—

Margins

Gross margin64.7%
Operating margin-33.6%
Net margin-32.6%
FCF margin-24.1%
EBITDA margin-31.3%

Returns

ROE-32.4%
ROA-23.3%
ROIC (approx.)-62.4%
Asset turnover0.72x

Leverage & solvency

Liabilities / assets30.6%
Debt / equity0.16x
Current ratio5.89x
Interest coverage-34.73x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-7.7%
Payout ratio—
Capex / revenue2.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$98.29M$94.50M$83.13M$76.38M$83.33M$79.18M$69.16M$68.24M
Cost of revenue$33.14M$32.12M$29.18M$30.07M$29.32M$27.44M$25.00M$24.56M
Gross profit$65.15M$62.38M$53.95M$46.31M$54.01M$51.75M$44.16M$43.67M
R&D expense$20.01M$20.10M$21.46M$19.06M$18.19M$17.63M$16.40M$15.07M
SG&A expense$72.51M$69.67M$65.09M$58.30M$59.01M$56.30M$55.20M$48.32M
Operating income-$27.38M-$27.39M-$32.61M-$31.04M-$23.19M-$22.19M-$27.44M-$19.71M
Interest expense$856,000$842,000$818,000$894,000$919,000$895,000$877,000$969,000
Pretax income-$26.57M-$26.77M-$31.68M-$29.78M-$21.38M-$19.44M-$24.78M—
Income tax-$58,000$94,000-$43,000$68,000$34,000$136,000-$47,000—
Net income-$26.52M-$26.86M-$31.64M-$29.84M-$21.41M-$19.58M-$24.74M-$18.86M
EBITDA-$24.84M-$25.40M-$30.87M-$29.33M-$21.57M-$20.60M-$25.96M-$18.26M
EPS (basic)-0.46-0.47-0.56—-0.38-0.35-0.45—
EPS (diluted)-0.46-0.47-0.56—-0.38-0.35-0.45—
Weighted avg. shares (diluted)57.33M57.07M56.51M—55.73M55.45M54.92M—
Banking
Provision for credit losses———————$384,000
Balance sheet
Cash & equivalents$218.37M$227.91M$245.64M$286.50M$294.28M$302.72M$316.21M$336.76M
Receivables$105.03M$107.61M$96.39M$83.53M$84.50M$80.82M$79.27M$83.50M
Inventory$81.41M$77.06M$77.54M$70.69M$66.72M$67.03M$62.33M$56.17M
Current assets$414.19M$420.29M$428.03M$450.38M$454.75M$458.07M$465.79M$481.84M
PP&E, net$30.16M$31.83M$31.74M$30.40M$30.02M$28.60M$28.13M$26.71M
Total assets$473.76M$479.35M$487.06M$508.08M$511.54M$513.05M$519.38M$534.02M
Current liabilities$70.35M$64.20M$63.64M$65.80M$53.90M$49.73M$52.06M$53.13M
Long-term debt$51.77M$51.72M$51.66M$51.62M$51.57M$51.52M$51.50M$51.47M
Total debt$51.77M$51.72M$51.66M$51.62M$51.57M$51.52M$51.50M$51.47M
Total liabilities$144.85M$139.28M$139.40M$142.21M$131.26M$127.26M$130.22M$131.80M
Shareholders' equity$328.91M$340.07M$347.67M$365.87M$380.28M$385.80M$389.16M$402.22M
Net debt-$166.60M-$176.20M-$193.98M-$234.89M-$242.72M-$251.19M-$264.71M-$285.29M
Shares outstanding57.44M57.25M56.90M56.32M55.87M55.58M55.28M54.72M
Cash flow statement
Operating cash flow-$8.98M-$19.25M-$38.13M-$10.33M-$6.63M-$15.04M-$16.98M-$32.39M
Capital expenditure$667,000$2.95M$2.91M$1.85M$2.87M$2.80M$1.84M$1.17M
Free cash flow-$9.65M-$22.20M-$41.04M-$12.18M-$9.50M-$17.84M-$18.82M-$33.56M
Investing cash flow-$667,000-$2.95M-$2.91M-$1.85M-$2.87M-$2.80M-$1.84M-$1.17M
Financing cash flow$99,000$4.50M$222,000$4.44M$1.08M$4.38M$1.30M$170.53M
Depreciation & amortization$2.54M$1.99M$1.74M$1.71M$1.62M$1.59M$1.48M$1.45M
Stock-based compensation$15.08M$14.53M$13.07M$10.84M$14.49M$12.16M$10.11M$9.09M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.